The stock hit a new high of ₹1,095, appreciated 117% from its 52-week low of ₹504.30 touched on January 28, 2025.

Indian equity markets remain in a tight range in the weekly expiry session on Thursday. However, pockets of opportunity are emerging, with SEBI-registered analysts Kavita Agrawal and Vinay Taparia ...

The FDA, which issued India’s Laurus Synthesis a Form 483 in January, followed up the action with an "untitled letter" (PDF) that outlined the Indian drugmaker’s problems with its quality control unit ...

When Dr Satyanarayana Chava started Laurus Labs in 2007, he invested nearly Rs 60 crore of his own money into it. His confidence in its success was neither bravado nor bluster, but defined by his ...

Laurus Labs latest update leaves the fair value estimate at roughly ₹821.93 per share with a steady discount rate of 12.76%, underscoring that the market narrative is shifting more on expectations ...

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Laurus Labs has seen its consensus analyst price target edge up slightly from ₹815.86 to ₹821.93. This signals renewed confidence among market watchers. This shift comes as experts weigh in on the ...

Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum ...

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a ...